Lorenzo Bertani

Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study

Purinergic Pathway Dysregulation in IBD and Pharmacological Efficacy of Dual P2X4R/P2X7R Blockade in Colitis (Abstract ID: 230061)

P0598 MIRACLE-UC: Mirikizumab Investigation of Real-world Assessment of Clinical and Long-term Effectiveness and Adverse Events in Patients with Ulcerative Colitis - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

DOP035 Upadacitinib: Personalized Goals for Remission and Disease Evaluation in Patients with Crohn’s Disease (UPGRADE-CD) - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study

P0587 Effectiveness and safety of Risankizumab in Crohn’s disease patients from a large Italian cohort: preliminary results from the RESOLVE IgIBD study

Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease

P539 Assessment of VEdolizumab aNd Ustekinumab in Elderly patients with Crohn’s disease (CD): the IG-IBD AVENUE study

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IG‐IBD LIVE</scp> study

Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study

Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

Fecal Clostridiales distribution and short‐chain fatty acids reflect bowel habits in irritable bowel syndrome

Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

Effect of <i>Lactobacillus paracasei</i> CNCM I‐1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial

P440 Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study

Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD

Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn

Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study

Proton pump inhibitor responders who are not confirmed as <scp>GERD</scp> patients with impedance and pH monitoring: who are they?